Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway

New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening

Philip Skehan, Ritsa Storeng, Dominic A. Scudiero et al. · JNCI Journal of the National Cancer Institute · 1990 · 9.8K citations

Medicine, Oncology, Pharmacology +10

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

William Pao, Vincent A. Miller, Katerina Politi et al. · PLoS Medicine · 2005 · 3.5K citations · Full text

Medicine, Oncology, Pharmacology +17

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

Sreenath V. Sharma, Diana Lee, Bihua Li et al. · Cell · 2010 · 2.8K citations · Full text

Life Sciences, Cancer Biology, Oncology +14

Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis

Gina M. DeNicola, Florian A. Karreth, Timothy J. Humpton et al. · Nature · 2011 · 2.2K citations · Full text

Life Sciences, Molecular Biology, Oncology +14

An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Lauren A. Byers, Lixia Diao, Jing Wang et al. · Clinical Cancer Research · 2012 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +17